Rapport Therapeutics (RAPP) Other financing activities (2024 - 2026)
Rapport Therapeutics' (RAPP) quarterly Other financing activities came in at $273000.0 in Q1 2026, up 4450.0% year-on-year from $6000.0 in Q1 2025, and down 61.33% on a QoQ basis from $706000.0 in Q4 2025.
Rapport Therapeutics (RAPP) Other financing activities (2024 - 2026) Analysis & Trends
Rapport Therapeutics (RAPP) has 3 years of Other financing activities data on file, last reported at $273000.0 in Q1 2026.
- On a quarterly basis, Other financing activities rose 4450.0% year-over-year to $273000.0 in Q1 2026; TTM through Mar 2026 was $1.6 million, a N/A change from a year earlier, with the FY2025 full-year figure at $1.3 million, up 19157.14% from the prior year.
- Other financing activities for Q1 2026 stood at $273000.0, down from $706000.0 in the prior quarter.
- Over the last five years, Other financing activities for RAPP reached as high as $706000.0 in Q4 2025 and fell as low as $6000.0 in Q1 2025.
- Historically, Other financing activities has averaged $380800.0 across 3 years, with a median of $283000.0 in 2024.
- Across the five-year window, Other financing activities slumped 97.88% in 2025 and jumped 4450.0% in 2026, its largest moves.
- Year by year, Other financing activities stood at $283000.0 in 2024, then surged by 149.47% to $706000.0 in 2025, then plunged by 61.33% to $273000.0 in 2026.
- Per Business Quant data, the three most recent Other financing activities figures were $273000.0 in Q1 2026, $706000.0 in Q4 2025, and $636000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Rapport Therapeutics | 1.95 Bn | 1.95 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 273,000.00 |
| Mar 31, 2026 | 273,000.00 |
| Dec 31, 2025 | 706,000.00 |
| Dec 31, 2025 | 706,000.00 |
| Sep 30, 2025 | 636,000.00 |
| Sep 30, 2025 | 636,000.00 |
| Mar 31, 2025 | 6,000.00 |
| Mar 31, 2025 | 6,000.00 |
| Mar 31, 2024 | 283,000.00 |
| Mar 31, 2024 | 283,000.00 |